

## WEST Search History

FILE COPY  
09/847, 355

DATE: Friday, August 16, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L3	L2 same virus	2	L3
L2	L1 same purging	43	L2
L1	neoplastic cells	4142	L1

END OF SEARCH HISTORY

## WEST Search History

FILE COPY  
09/847,355

DATE: Friday, August 16, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L12	L9 and organ	25	L12
L11	L9 and tissue	43	L11
L10	L9 and hematopoietic	20	L10
L9	L3 same (treatment)	57	L9
L8	L3 and (organ)	103	L8
L7	L3 and (tissue)	211	L7
L6	L3 same (organ)	10	L6
L5	L3 same (tissue)	63	L5
L4	L3 same (hematopoietic)	11	L4
L3	L1 same (virus)	291	L3
L2	L1 same (mixed cellular composition)	3	L2
L1	neoplastic cell	4142	L1

END OF SEARCH HISTORY

FILE COPY

09/847,355

DIALOG

Set	Items	Description
S1	2526	NEOPLASTIC CELL?
S2	10	S1 AND PURGING
S3	0	S2 AND VIRUS
S4	10	RD S2 (unique items)
S5	10	S2 NOT PY>2000
S6	454	S1 AND VIRUS
S7	84	S1 AND HEMATOPOIETIC
S8	7	S6 AND HEMATOPOIETIC
S9	7	RD S8 (unique items)
S10	6	S9 NOT PY>2000

? t s5/medium/1-10  
>>>"MEDIUM" is not a valid format name in file(s): 41

5/3/1 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13086694 BIOSIS NO.: 200100293843

Real time PCR for molecular monitoring of minimal residual disease in multiple myeloma patients undergoing autologous transplantation with in vitro purged hematopoietic stem cells.

AUTHOR: Barbui A M(a); Dotti G(a); Barbui T(a); Rambaldi A(a)

AUTHOR ADDRESS: (a)Divisione di Ematologia, Ospedali Riuniti, Bergamo\*\* Italy

JOURNAL: Blood 96 (11 Part 1):p184a November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

5/3/2 (Item 2 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

10884795 BIOSIS NO.: 199799505940

A new 'two step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation.

AUTHOR: Bertolini F(a); Thomas T; Battaglia M; Gibelli N; Pedrazzoli P; Robustelli Della Cuna G

AUTHOR ADDRESS: (a)Div. Med. Oncol., IRCCS Maugeri Found., Pavia Med. Cent., viale Boezio 26, 27100 Pavia\*\*Italy

JOURNAL: Bone Marrow Transplantation 19 (6):p615-619 1997

ISSN: 0268-3369

RECORD TYPE: Abstract

LANGUAGE: English

5/3/3 (Item 3 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

10047551 BIOSIS NO.: 199598502469

Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging.

AUTHOR: Douay Luc(a); Hu Chen; Giarratana Marie-Catherine; Bouchet Sandrine ; Conlon John; Capizzi Robert L; Gorin Norbert-Claude

AUTHOR ADDRESS: (a)Lab. Hematologie, Hopital de'enfants Armand Trousseau, 26 Ave. du Docteur Arnold Netter, 75571 P\*\*France

JOURNAL: Blood 86 (7):p2849-2855 1995

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/4 (Item 4 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

09263389 BIOSIS NO.: 199497271759

Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.

AUTHOR: Lemoli R M(a); Tazzari P L; Fortuna A; Bolognesi A; Gulati S C; Stirpe F; Turà S

AUTHOR ADDRESS: (a) Inst. Ematol. Seragnoli, Univ. Bologna, Via Massarenti 9, 40138 Bologna\*\*Italy

JOURNAL: Bone Marrow Transplantation 13 (4):p465-471 1994

ISSN: 0268-3369

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/5 (Item 1 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00326488

IDENTIFYING NO.: 5R01GM38645-12 AGENCY CODE: CRISP  
CLASSIFIERS FOR HIGH SPEED, HIGH-RESOLUTION CELL SORTING  
PRINCIPAL INVESTIGATOR: LEARY, JAMES F  
ADDRESS: UNIV OF TEXAS MEDICAL BRANCH 301 UNIVERSITY BLVD GALVESTON, TX 77555-0835  
PERFORMING ORG.: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON, GALVESTON, TEXAS  
SPONSORING ORG.: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES  
FY : 2001

5/3/6 (Item 2 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00307700

IDENTIFYING NO.: 2R44CA84924-02 AGENCY CODE: CRISP  
TUMOR CELL PURGING USING FLUORESCENT ANTIBODIES  
PRINCIPAL INVESTIGATOR: HANANIA, ELIE G  
ADDRESS: ONCOSIS 6199 CORNERSTONE CT SUITE 111 SAN DIEGO, CA 92121-4740  
PERFORMING ORG.: ONCOSIS, INC., SAN DIEGO, CALIFORNIA  
SPONSORING ORG.: NATIONAL CANCER INSTITUTE  
FY : 2001

5/3/7 (Item 3 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00306200

IDENTIFYING NO.: 5R01CA79763-03 AGENCY CODE: CRISP  
SELECTIVE THERAPY OF NEUROBLASTOMA  
PRINCIPAL INVESTIGATOR: POTTER, PHILIP M  
ADDRESS: ST JUDE CHILDRENS RES HOSP 332 NORTH LAUDERDALE MEMPHIS, TN 38105  
PERFORMING ORG.: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TENNESSEE  
SPONSORING ORG.: NATIONAL CANCER INSTITUTE  
FY : 2001

5/3/8 (Item 4 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00305960

IDENTIFYING NO.: 5R21CA78693-02 AGENCY CODE: CRISP  
PROGENITOR COLONY RT-PCR ANALYSIS IN CML TREATMENT  
PRINCIPAL INVESTIGATOR: EHRLICH, MELANIE  
ADDRESS: TULANE UNIV MEDICAL CENTER 1430 TULANE AVE NEW ORLEANS, LA 70112  
PERFORMING ORG.: TULANE UNIVERSITY OF LOUISIANA, NEW ORLEANS, LOUISIANA  
SPONSORING ORG.: NATIONAL CANCER INSTITUTE  
FY : 2001

5/3/9 (Item 5 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00304986

IDENTIFYING NO.: 5R29CA75113-06 AGENCY CODE: CRISP  
REGULATED TOXIN GENE THERAPY FOR RHABDOMYOSARCOMA  
PRINCIPAL INVESTIGATOR: CRIPE, TIMOTHY P  
ADDRESS: CHILDREN'S HOSPITAL MEDICAL CT 3333 BURNET AVENUE CINCINNATI, OH 45229  
PERFORMING ORG.: CHILDREN'S HOSPITAL MED CTR (CINCINNATI), CINCINNATI, OHIO  
SPONSORING ORG.: NATIONAL CANCER INSTITUTE  
FY : 2001

5/3/10 (Item 6 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00304736

IDENTIFYING NO.: 5K08CA73825-04 AGENCY CODE: CRISP  
CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA  
PRINCIPAL INVESTIGATOR: NOY, ARIELA  
ADDRESS: MEM SLOAN KETTERING CANCER CTR 1275 YORK AVE NEW YORK, NY 10021  
PERFORMING ORG.: SLOAN-KETTERING INSTITUTE FOR CANCER RES, NEW YORK, NEW YORK  
SPONSORING ORG.: NATIONAL CANCER INSTITUTE  
FY : 2001

? t s5/k/1-10

>>>KWIC option is not available in file(s): 41, 77, 399

5/K/1 (Item 1 from file: 5)

DIALOG(R) File 5:(c) 2002 BIOSIS. All rts. reserv.

...ABSTRACT: and no transplant related mortality has been seen so far.  
Before and after in vitro **purg**ing, minimal residual disease (MRD)  
was evaluated by Real Time (RT) quantitative and semi quantitative PCR...

...cells (range 103-105) and confirmed the significant tumor cells  
debulking obtained by in vitro **purg**ing. A prospective in vivo  
evaluation of MRD is currently undergoing by this Real-time PCR...

DESCRIPTORS:

...ORGANISMS: PARTS ETC: **neoplastic cell**  
CHEMICALS & BIOCHEMICALS: ...**neoplastic cell contamination**  
...METHODS & EQUIPMENT: contaminant **purg**ing, equipment...

...contaminant **purg**ing, equipment...

...contaminant **purg**ing, equipment...

5/K/2 (Item 2 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

ABSTRACT: To evaluate a new 'two step' method for **purgi**ng T, B and neoplastic cells from hematopoietic progenitor cells (PC), PCs were collected by apheresis...

...7%, T and B cell removal was 4.7 +- 0.4 log and neoplastic cell **purgi**ng was 4.4 +- 0.3 log, i.e. significantly superior to methods described in the...

MISCELLANEOUS TERMS: ...NEOPLASTIC CELLS...

...PURGING METHOD

5/K/3 (Item 3 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow **purgi**ng.

...ABSTRACT: cells by protecting normal tissues. One potential application of this protector is during bone marrow **purgi**ng to selectively remove contaminating cancer cells. This study took normal or leukemic marrow from human...

...cells allows a higher LD-95 concentration of mafosfamide to be used in *ex vivo* **purgi**ng. In contrast, amifostine pretreatment increased the cytotoxicity of mafosfamide on the fresh human leukemia progenitor...

MISCELLANEOUS TERMS: ...NEOPLASTIC CELL

5/K/4 (Item 4 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Positive selection of hematopoietic CD34+ stem cells provides 'indirect **purgi**ng' of CD34- lymphoid cells and the **purgi**ng efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.

...ABSTRACT: tumor cells from the enriched CD34+ cell fraction was demonstrated. To increase the neoplastic cell **purgi**ng, several immunotoxins (IT) containing the ribosome-inactivating protein (RIP) saporin and directed toward the lymphoid...

...CD34+ cells purification and IT treatment resulted in 5 or more log of tumor cell **purgi**ng with no additional loss of BM progenitor cells.

MISCELLANEOUS TERMS: ...NEOPLASTIC CELL PURGING;

5/K/5 (Item 1 from file: 266)  
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

...SUMMARY: biology. For clinical research, applications such as stem cell isolati on (with perhaps simultaneous tumor **purgi**ng and gene therapy) are on the horizon . For commercial applications, high-speed sorting of bacterial...

...DESCRIPTORS: evaluation; computer program /software; human subject; classification; data collection methodology /evaluation; statistics /biometry; breast neoplasm; **neoplastic cell**; metastasis; cell population study; digital imaging; cell line; clinical research; stem cell

5/K/6 (Item 2 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

**TUMOR CELL PURGING USING FLUORESCENT ANTIBODIES**

...SUMMARY: Therefore, technology that reliably eliminates detectable tumor cells, while leaving HSCs undamaged, is needed. Several **purgung** methods have been developed, but they are known to be inadequate. An innovative approach integrating...

... and killing every detectable tumor cell, provides a unique opportunity to evaluate the efficacy of **purgung** in a setting where information on total tumor burden within the transplant is generated, down...

... the level of one detectable cell within the transplant. Although this proposal describes a tumor **purgung** application, there are numerous other research and clinical applications that will be enabled once the...

...DESCRIPTORS: cytometry; computer program /software; fluorescent dye /probe; human tissue; monoclonal antibody; tumor antigen; breast neoplasm; **neoplastic cell**; image processing; laser; autologous transplantation; technology /technique development; nonHodgkin's lymphoma; bone marrow **purgung**; charge coupled device camera; bioimaging /biomedical imaging ; stem cell transplantation

5/K/7 (Item 3 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

...SUMMARY: of this approach as a potential treatment for minimum residual disease and in the **purgung** of marrow for autologous transplant. The goals of this proposal are to determine: 1) the...

...DESCRIPTORS: prodrug; enzyme inhibitor; gene expression; genetic promoter element; genetic transcription; transcription factor; human tissue ; neuroblastoma; **neoplastic cell**; neoplasm /cancer chemotherapy; DNA topoisomerase; complementary DNA; protein structure function; cytotoxicity; enzyme activity; CD34...

5/K/8 (Item 4 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

...SUMMARY: conducted of CML patients undergoing a new treatment protocol involving an induction regimen, in vivo **purgung** , stem cell mobilization into the peripheral blood, leukapheresis, autologous peripheral blood stem cell transplantation and...

... contamination of peripheral blood samples and bone marrow samples with leukemic cells after in vivo **purgung**. Also, the proposed analysis will provide needed preliminary data for a larger study to test...

...DESCRIPTORS: myeloid stem cell; leukapheresis; polymerase chain reaction; prognosis; cytogenetics; human subject; oncoprotein; chronic myelogenous leukemia; **neoplastic cell**; neoplasm /cancer relapse /recurrence; neoplasm /cancer chemotherapy; RNA; human therapy evaluation; tissue /cell culture...

5/K/9 (Item 5 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

...SUMMARY: eliminating tumor cells from a mixed cell population as a model for autologous bone marrow **purgung** will also be tested. Conditions for in vivo gene transfer to human xenografted tumor cells...

...DESCRIPTORS: immunoconjugate; bacterial toxin; disease /disorder model ; neoplasm /cancer genetics; rhabdomyosarcoma; lung neoplasm; neoplasm /cancer transplantation; **neoplastic cell**; cell population study; DNA binding protein; lung alveolus; tissue /cell culture; autologous transplantation; Adenoviridae; bone marrow **purg**ing; SCID mouse

5/K/10 (Item 6 from file: 266)  
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All  
rts. reserv.

...DESCRIPTORS: subject; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer immunology; lymphoma; **neoplastic cell**; autologous transplantation; human genetic material tag; bone marrow **purg**ing; chronic lymphocytic leukemia; clinical research; minimal residual disease; outcomes research ?

? t s10/medium/1-6  
>>>"MEDIUM" is not a valid format name in file(s): 41

10/3/1 (Item 1 from file: 94)  
DIALOG(R)File 94:JICST-EPlus  
(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

02676587 JICST ACCESSION NUMBER: 96A0128640 FILE SEGMENT: JICST-E  
c-Cbl Is Inducibly Tyrosine-phosphorylated by Epidermal Growth Factor  
Stimulation in Fibroblasts, and Constitutively Tyrosine-phosphorylated  
and Associated with v-Src in v-src-transformed Fibroblasts.  
ODAI H (1); SASAKI K (1); HANAZONO Y (1); UENO H (1); TANAKA T (1);  
MIYAGAWA K (1); MITANI K (1); YAZAKI Y (1); HIRAI H (1)  
(1) Univ. Tokyo, Tokyo  
Jpn J Cancer Res, 1995, VOL.86, NO.12, PAGE.1119-1126, FIG.5, REF.40  
JOURNAL NUMBER: F0633ABW ISSN NO: 0910-5050  
UNIVERSAL DECIMAL CLASSIFICATION: 616-006.2  
LANGUAGE: English COUNTRY OF PUBLICATION: Japan  
DOCUMENT TYPE: Journal  
ARTICLE TYPE: Short Communication  
MEDIA TYPE: Printed Publication

10/3/2 (Item 2 from file: 94)  
DIALOG(R)File 94:JICST-EPlus  
(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

01871392 JICST ACCESSION NUMBER: 93A0662171 FILE SEGMENT: JICST-E  
Introduction of Foreign Gene into Reaggregate-Cultured Hepatocytes, and  
Their Transplantation.  
OGAWA KATSUHIRO (1); NISHIKAWA YUJI (1); INAGAKI MITSUHIRO (1); MITO MICHIO  
(1)  
(1) Asahikawa Medical College  
Gekkan Soshiki Baiyo(Tissue Culture), 1993, VOL.19, NO.9, PAGE.336-339,  
FIG.3, TBL.1, REF.10  
JOURNAL NUMBER: F0781BAM ISSN NO: 0386-1791  
UNIVERSAL DECIMAL CLASSIFICATION: 57.086 616/618-76/78  
LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan  
DOCUMENT TYPE: Journal  
ARTICLE TYPE: Commentary  
MEDIA TYPE: Printed Publication

10/3/3 (Item 3 from file: 94)  
DIALOG(R)File 94:JICST-EPlus  
(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

01629300 JICST ACCESSION NUMBER: 92A0600952 FILE SEGMENT: JICST-E  
Transcription Factors in Hemopoietic Cell Differentiation.  
NAKANO TOORU (1)  
(1) Kyoto Univ. Faculty of Medicine  
Saibo Kogaku(Cell Technology), 1992, VOL.11, NO.7, PAGE.474-480, FIG.2,  
TBL.1, REF.44  
JOURNAL NUMBER: Y0229AAZ ISSN NO: 0287-3796  
UNIVERSAL DECIMAL CLASSIFICATION: 591.111.05+591.41  
LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan  
DOCUMENT TYPE: Journal  
ARTICLE TYPE: Commentary  
MEDIA TYPE: Printed Publication

10/3/4 (Item 1 from file: 266)  
DIALOG(R)File 266:FEDRIP  
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00363827

IDENTIFYING NO.: 1Z01SC00550-21 AGENCY CODE: CRISP  
Immunologic Characterization of Malignant Lymphomas  
PRINCIPAL INVESTIGATOR: JAFFE, ELAINE  
ADDRESS: NCI SC, NIH  
SPONSORING ORG.: DIVISION OF CLINICAL SCIENCES - NCI  
FY : 2001

10/3/5 (Item 2 from file: 266)

DIALOG(R) File 266:FEDRIP  
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00334537

IDENTIFYING NO.: 1Z01HG00077-03 AGENCY CODE: CRISP  
TRANSCRIPTION: TARGETING/CONDITIONAL EXPRESSION OF TRANSGENE--CANCER  
IMMUNOTHERAPY  
PRINCIPAL INVESTIGATOR: XANTHOPOULOS, K G.  
ADDRESS: NHGRI, NIH  
SPONSORING ORG.: NATIONAL HUMAN GENOME RESEARCH INSTITUTE  
FY : 2001

10/3/6 (Item 3 from file: 266)

DIALOG(R) File 266:FEDRIP  
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00300108

IDENTIFYING NO.: 1Z01BC05598-12 AGENCY CODE: CRISP  
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells  
PRINCIPAL INVESTIGATOR: GOTTESMAN, MICHAEL M  
ADDRESS: NCI BC, NIH  
SPONSORING ORG.: DIVISION OF BASIC SCIENCES - NCI  
FY : 2001

? t-s10/k/1-6

>>>KWIC option is not available in file(s): 41, 77, 399

10/K/1 (Item 1 from file: 94)

DIALOG(R) File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.  
reserv.

...ABSTRACT: implicated in the signal transduction triggered by  
granulocyte-macrophage colony-stimulating factor or erythropoietin in  
hematopoietic cells. Here, we observed tyrosine phosphorylation of  
c-Cbl in cells expressing epidermal growth factor...

...those of EGF receptor and Src protein, as well as in the signaling  
pathways of hematopoietic cells. (author abst.)

...DESCRIPTORS: neoplastic cell transformation

...BROADER DESCRIPTORS: RNA virus; ...

...virus; ...

...animal virus;

10/K/2 (Item 2 from file: 94)

DIALOG(R) File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.  
reserv.

...DESCRIPTORS: neoplastic cell transformation

...BROADER DESCRIPTORS: RNA virus; ...

...virus; ...  
...animal virus; ...  
...virus genom...  
...virus component...  
...hematopoietic organ

10/K/3 (Item 3 from file: 94)  
DIALOG(R)File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.  
reserv.

DESCRIPTORS: hematopoietic stem cell...

...neoplastic cell transformation  
...BROADER DESCRIPTORS: tumor virus; ...  
...virus; ...  
...RNA virus; ...  
...animal virus;

10/K/4 (Item 1 from file: 266)  
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All  
rts. reserv.

...SUMMARY: females. We also have characterized blastic NK cell lymphomas, as a for m of primitive hematopoietic malignancy frequently involving the skin with a hig h incidence of bone marrow involvement and...

...DESCRIPTORS: tissue; cytokine; lymphokine; immunogenetics; monoclonal antibody; neoplasm /cancer immunology; antitumor antibody; lymphoma; Burkitt's lymphoma; neoplastic cell; Epstein Barr virus; phenotype; chemokine

10/K/5 (Item 2 from file: 266)  
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All  
rts. reserv.

...SUMMARY: EBP-alpha and C/EBP-epsilon, in cell proliferation and differentiation of hepatocytes, adipocytes and hematopoietic cells respectively. We study their the functional roles in vivo using homologous recombination for targeted...

... human cancers. This strategy is based on (i) highly efficient alphaviruses, e,g. Semliki Forest Virus (SFV) and (ii) hybrid Adenoviral/SFV chimeric vectors. SFV has several advantages over existing vectors...

DESCRIPTORS: laboratory mouse; transgenic animal; biological signal transduction; hematopoietic stem cell; cell differentiation; adipocyte; gene therapy; genetic manipulation; developmental genetics; genetic transcription; cytokine; liver cell; neoplasm /cancer immunotherapy ; neoplastic cell; Adenoviridae; Alphavirus; transfection /expression vector; gene targeting; enhancer binding protein

10/K/6 (Item 3 from file: 266)  
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All

rts. reserv.

...SUMMARY: in the packaged DNA. This approach offers promise for transfer of Pgp into **hematopoietic** and other cells for gene therapy. We have also shown in a canine model...

...DESCRIPTORS: structure; gene therapy; genetic marker; gene expression; fungal genetics; cis platinum compound; adenocarcinoma; multidrug resistance; **neoplastic cell**; adenosinetriphosphatase; drug receptor; vaccinia **virus**; human genetic material tag; P glycoprotein; phenotype ; enzyme activity; transfection /expression vector; green fluorescent protein

?